Actively Recruiting
Evaluation of Safety and Immune Response to Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env VRIPRO Vaccine in Adults Previously in HVTN 706
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-09-18
40
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and immune response of Hiltonol, a Poly-ICLC-adjuvanted CD40.HIVRI.Env VRIPRO vaccine in adults aged 18 to 60 years who previously participated in the HVTN 706 trial. This Phase 1, open-label, non-randomized clinical trial focuses on preventing HIV infections by studying this vaccine in healthy volunteers without HIV. Participants will receive three subcutaneous injections of the CD40.HIVRI.Env VRIPRO vaccine mixed with Hiltonol at weeks 0, 4, and 24. The study includes those who received either the vaccine or placebo in the previous HVTN 706 trial. Throughout the study, safety and immune responses to the vaccine will be closely monitored. During the trial, participants will be assessed for local and systemic reactions for at least 14 days after each vaccine dose. Safety monitoring will continue for up to one year after vaccination, including tracking serious adverse events and other health changes. Researchers will measure various immune responses, including antibody levels and T-cell activity, to evaluate the vaccines effects. Participants will be followed through all clinic visits and contacted 12 months after the last dose, with the total study duration extending to November 2027.
CONDITIONS
Brief Title
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here